Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis

Treatment for visceral leishmaniasis (VL) is hampered mainly by drug toxicity, their high cost, and parasite resistance. Drug development is a long and pricey process, and therefore, drug repositioning may be an alternative worth pursuing. Cardenolides are used to treat cardiac diseases, especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Freitas, Camila S., Oliveira-da-Silva, João A., Lage, Daniela P., Costa, Rafaella R., Mendonça, Débora V. C., Martins, Vívian T., Reis, Thiago A. R., Antinarelli, Luciana M. R., Machado, Amanda S., Tavares, Grasiele S. V., Ramos, Fernanda F., Coelho, Vinicio T. S., Brito, Rory C. F., Ludolf, Fernanda, Chávez-Fumagalli, Miguel A., Roatt, Bruno M., Ramos, Gabriela S., Munkert, Jennifer, Ottoni, Flaviano M., Campana, Priscilla R. V., Humbert, Maria V., Coimbra, Elaine S., Braga, Fernão C., Pádua, Rodrigo M., Coelho, Eduardo A. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Treatment and Prophylaxis - Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667010/
https://www.ncbi.nlm.nih.gov/pubmed/33191446
http://dx.doi.org/10.1007/s00436-020-06971-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667010/
https://www.ncbi.nlm.nih.gov/pubmed/33191446
http://dx.doi.org/10.1007/s00436-020-06971-2

Ejemplares similares